This favors cancer hallmarks such as epithelial‐mesenchymal transition (EMT), apoptosis resistance, angiogenesis, and tumor proliferation, impacting systemic immune changes and worsening clinical and pathological prognostic parameters.[47, 48, 49] Intriguingly, we highlight for the first time how survival is affected by the strong correlation between STAT3/NF‐κB pathways, M2‐TAM, oncogenic HPV/XPO5, systemic immunosuppression (via blood immunosuppressive cytokines), and FoxP3/HLA‐G polymorphisms. This evidence concerns the gene STAT3 and cancer.